An observational study in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by University of Colorado, Denver. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by University of Colorado, Denver · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 138 studies in Esophageal Squamous Cell Carcinoma with a site in United States — 42 open to participants now, 50 under way, 3 of them phase 3. Esophageal Squamous Cell Carcinoma · United States.
Among the 138 studies in Esophageal Squamous Cell Carcinoma with a site in United States, this one is the only one that started in 2027, is one of 6 observational ones, reaches primary completion later than 45 of the 49 other live ones, and was the 138th registered.
678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 267 are open to participants now.
Browse Esophageal Squamous Cell Carcinoma studies →42 of the 138 studies in Esophageal Squamous Cell Carcinoma with a site in United States are open now. Recruiting first, the newest first:
Crescent Biopharma, Inc. · Sites in United States
Ages 18+
Jonsson Comprehensive Cancer Center · Sites in United States
Ages 18+
Astellas Pharma Global Development, Inc. · Sites in United States, Japan
Ages 18+
InduPro, Inc. · Sites in United States
Ages 18+
BeOne Medicines · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
138 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 61 · Phase 2 68 · Phase 3 12
First in 1992; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is below the median of 239 across 87 observational studies indexed under Esophageal Squamous Cell Carcinoma.
Median enrollment 61 across the 120 interventional studies, 360 across the 6 observational. Of the 85 that completed or were terminated, 29 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
65 of 138 have an industry lead sponsor. The 10 most frequent:
University of Colorado, Denver is the lead sponsor of 1,544 studies on the registry; 318 are open to participants now.
Of its 147 completed or terminated interventional studies of FDA-regulated products, 92 (63%) have results posted.
University of Colorado, Denver has 1 study filed under Esophageal Squamous Cell Carcinoma — fewer than ten, so there is no comparison to draw.
13 of the studies in Esophageal Squamous Cell Carcinoma with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04550260Phase 3AstraZenecaStudy of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC | 2027-06-30 |
| NCT06545331ExelixisStudy of XB010 in Subjects With Solid Tumors | 2026-11-23 |
| NCT04510129Cofactor Genomics, Inc.A Multicenter Cancer Biospecimen Collection Study | 2027-02 |
| NCT06047379Neonc Technologies, Inc.Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | 2027-02-28 |
| NCT04221893University of California, San FranciscoRadiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers | 2027-04-30 |
Add all 13 to your calendar (.ics) → With an account.
Among the 138 studies in Esophageal Squamous Cell Carcinoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to determine whether circulating tumor DNA (ctDNA) clearance at the completion of chemoradiotherapy (chemotherapy and radiation therapy) can predict durable complete response in adults with localized esophageal squamous cell carcinoma (ESCC). ctDNA clearance refers to the disappearance of detectable tumor DNA from the blood after treatment.
Current methods used to assess treatment response, including imaging scans (PET/CT) and endoscopy, have limitations in reliably identifying patients who achieve a durable complete response after chemoradiotherapy. Researchers will evaluate whether ctDNA clearance improves the prediction of durable complete response beyond standard response assessments. The findings may help identify patients suitable for non-operative management with active surveillance.
The main questions this study aims to answer are:
The study will enroll approximately 120 adults with localized esophageal squamous cell carcinoma undergoing curative-intent chemoradiotherapy as part of standard clinical care.
Study participants will:
Researchers will compare ctDNA results with standard clinical response assessments, including PET/CT and endoscopy, and clinical outcomes. Researchers will also assess whether ctDNA results influence physician treatment recommendations and clinical decision-making in the Longitudinal ctDNA Cohort.
This observational study does not involve investigational therapeutic interventions or require changes to standard clinical management. The findings may help improve risk stratification and identify patients suitable for organ-preservation strategies or closer surveillance following chemoradiotherapy.
Adults aged 18 years or older with histologically confirmed, localized cervical or thoracic esophageal squamous cell carcinoma (ESCC), clinical stage cT1-4 or cTX, N0-3, M0, who are planned to receive curative-intent definitive chemoradiotherapy with active surveillance or neoadjuvant chemoradiotherapy followed by planned esophagectomy.
Eligible participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, adequate pretreatment tumor tissue for tumor-informed circulating tumor DNA (ctDNA) assay generation, and the ability to undergo protocol-specified blood collection.
Participants will be enrolled into one of two observational cohorts: the Longitudinal ctDNA Cohort or the Limited-Sampling Research Cohort. Cohort assignment will be based on participant election, treatment location, and operational feasibility. Participants may receive chemoradiotherapy at participating study sites or, for eligible participants in the Limited-Sampling Research Cohort,
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The Longitudinal ctDNA Cohort additionally obtains ctDNA at 6 weeks post-CRT, 3 months post-CRT, and every 3 months through 24 months, and physician decision-impact surveys assess whether ctDNA findings influence clinical management.
Diagnostic Test: Tumor-Informed ctDNA Assessment (Signatera™ Genome Assay)
Participants in the Limited-Sampling Research Cohort undergo tumor-informed ctDNA assessment at baseline, Week 3 of CRT, and completion of CRT. Results are returned through routine clinical workflows. No physician decision-impact surveys are administered, and no protocol-directed ctDNA collections occur after completion of CRT. Clinical outcome data are collected through approximately 24 months following CRT.
Diagnostic Test: Tumor-Informed ctDNA Assessment (Signatera™ Genome Assay)
Peripheral blood samples are collected for tumor-informed circulating tumor DNA (ctDNA) assessment using the Signatera™ Genome Assay. ctDNA testing is performed at protocol-defined time points to evaluate ctDNA clearance and kinetics in participants with localized esophageal squamous cell carcinoma undergoing standard-of-care chemoradiotherapy. Results are returned through routine clinical workflows; no protocol-mandated treatment modifications are required based on ctDNA results.
Percentage of Participants Achieving 2-Year Complete Response-Disease-Free Survival (CR-DFS)
The percentage of participants achieving 2-year complete response-disease-free survival (CR-DFS) across both neoadjuvant and definitive chemoradiotherapy (CRT) pathways. CR-DFS is defined as pathologic complete response (ypT0N0) among participants undergoing esophagectomy or sustained clinical complete response among participants managed with definitive CRT and active surveillance, without locoregional recurrence, distant recurrence, death, or requirement for salvage esophagectomy within 24 months of completing CRT. The primary analysis will compare 2-year CR-DFS rates between participants with and without circulating tumor DNA (ctDNA) clearance at completion of CRT, stratified by treatment pathway. ctDNA clearance is defined as conversion from detectable ctDNA at baseline to an undetectable result at completion of CRT. A common odds ratio with a 95% confidence interval will be reported.
Time frame: From completion of chemoradiotherapy through 24 months post-chemoradiotherapy.
Sensitivity of ctDNA Clearance for Predicting 2-Year CR-DFS
Sensitivity of ctDNA clearance at completion of CRT for identifying participants who achieve 2-year CR-DFS, calculated using ctDNA clearance status and the observed 2-year clinical outcome. Diagnostic performance will be summarized with 95% confidence intervals.
Time frame: Baseline and completion-of-CRT ctDNA assessment; clinical outcome assessment through 24 months post-CRT.
Specificity of ctDNA Clearance for Predicting 2-Year CR-DFS
Specificity of ctDNA clearance at completion of CRT for identifying participants who do not achieve 2-year CR-DFS, calculated using ctDNA clearance status and the observed 2-year clinical outcome. Diagnostic performance will be summarized with 95% confidence intervals.
Time frame: Baseline and completion-of-CRT ctDNA assessment; clinical outcome assessment through 24 months post-CRT.
Positive Predictive Value of ctDNA Clearance for Predicting 2-Year CR-DFS
Positive predictive value of ctDNA clearance at completion of CRT for identifying participants who achieve 2-year CR-DFS. Diagnostic performance will be summarized with 95% confidence intervals
Time frame: Baseline and completion-of-CRT ctDNA assessment; clinical outcome assessment through 24 months post-CRT.
Negative Predictive Value of ctDNA Clearance for Predicting 2-Year CR-DFS
Negative predictive value of ctDNA clearance at completion of CRT for identifying participants who do not achieve 2-year CR-DFS. Diagnostic performance will be summarized with 95% confidence intervals.
Time frame: Baseline and completion-of-CRT ctDNA assessment; clinical outcome assessment through 24 months post-CRT.
Area Under the Receiver Operating Characteristic Curve (AUC) for ctDNA Clearance, PET/CT, Endoscopy, and Combined Models in Predicting 2-Year CR-DFS
Area under the receiver operating characteristic curve (AUC) for ctDNA clearance, PET/CT response, endoscopic response, and combined models for predicting 2-year CR-DFS. Comparative and additive predictive performance will be evaluated to assess the incremental predictive value of ctDNA clearance over standard post-treatment response assessment.
Time frame: Post-treatment response assessment following completion of CRT; clinical outcome assessment through 24 months post-CRT.
Association Between ctDNA Clearance at Week 3 of CRT and 2-Year CR-DFS
Association between ctDNA clearance status at the specified landmark timepoint and subsequent 2-year complete response-disease-free survival (CR-DFS). ctDNA clearance is evaluated using the tumor-informed Signatera Genome Assay. Associations with 2-year CR-DFS will be evaluated using the statistical methods specified in the protocol.
Time frame: Baseline and Week 3 of CRT; outcomes through 24 months post-CRT
Association Between ctDNA Clearance at Completion of CRT and 2-Year CR-DFS
Association between ctDNA clearance status at the specified landmark timepoint and subsequent 2-year complete response-disease-free survival (CR-DFS). ctDNA clearance is evaluated using the tumor-informed Signatera Genome Assay. Associations with 2-year CR-DFS will be evaluated using the statistical methods specified in the protocol.
Time frame: Baseline and Week 5 of chemoradiotherapy for thoracic tumors or Week 7 of chemoradiotherapy for cervical tumors; clinical outcomes assessed up to 24 months after completion of chemoradiotherapy
Association Between ctDNA Clearance at 6 Weeks Post-CRT and 2-Year CR-DFS
Association between ctDNA clearance status at the specified landmark timepoint and subsequent 2-year complete response-disease-free survival (CR-DFS). ctDNA clearance is evaluated using the tumor-informed Signatera Genome Assay. Associations with 2-year CR-DFS will be evaluated using the statistical methods specified in the protocol.
Time frame: Baseline through 6 weeks post-CRT; outcomes through 24 months post-CRT
Association Between ctDNA Clearance at 3 Months Post-CRT and 2-Year CR-DFS
Association between ctDNA clearance status at the specified landmark timepoint and subsequent 2-year complete response-disease-free survival (CR-DFS). ctDNA clearance is evaluated using the tumor-informed Signatera Genome Assay. Associations with 2-year CR-DFS will be evaluated using the statistical methods specified in the protocol.
Time frame: Baseline through 3 months post-CRT; outcomes through 24 months post-CRT
Percentage of Participants With Physician-Reported Changes in Clinical Management Attributable to ctDNA Results
Frequency and type of physician-reported changes in treatment recommendations or surveillance strategy attributable to ctDNA results, including additional diagnostic testing and/or changes in clinical management. Changes will be assessed using the CLEAR-ESO Physician Decision-Impact Survey in the Longitudinal ctDNA Cohort only.
Time frame: At 3 months and 24 months post-CRT and whenever ctDNA results influence clinical management, through 24 months post-CRT.
Percentage of Participants With ctDNA Clearance According to Baseline Tumor Characteristics
The percentage of participants achieving circulating tumor DNA (ctDNA) clearance at completion of chemoradiotherapy (CRT) will be evaluated according to baseline tumor characteristics, including clinical tumor stage, nodal stage, tumor length (cranial-caudal extent), baseline ctDNA burden, and cervical versus thoracic tumor location. ctDNA clearance is defined as conversion from detectable ctDNA at baseline to an undetectable result at completion of CRT.
Time frame: Baseline through completion of chemoradiotherapy (approximately Week 5 for thoracic tumors and up to Week 7 for cervical tumors).
Percentage of participants with Locoregional or Distant Recurrence according to ctDNA Status
The percentage of participants experiencing locoregional or distant recurrence will be evaluated according to circulating tumor DNA (ctDNA) status during surveillance. Recurrence patterns will be characterized using available clinical and radiographic assessments.
Time frame: From completion of chemoradiotherapy through 24 months post-chemoradiotherapy.
Time From ctDNA Positivity to Radiographic or Clinical Recurrence
Interval from ctDNA positivity during surveillance to radiographic or clinical recurrence among participants with documented recurrence. This analysis will characterize the timing of recurrence relative to ctDNA status in the Longitudinal ctDNA Cohort.
Time frame: From completion of CRT through 24 months post-CRT.
Start is estimated for Jun 2027; primary completion for Aug 2030, 38 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Esophageal Squamous Cell Carcinoma →
University of Colorado, Denver →